about
Nano scale self-emulsifying oil based carrier system for improved oral bioavailability of camptothecin derivative by P-Glycoprotein modulation.Microemulsions as a surrogate carrier for dermal drug delivery.Advances and potential applications of chitosan derivatives as mucoadhesive biomaterials in modern drug delivery.Dental therapeutic systems.Enhanced transdermal drug delivery techniques: an extensive review of patents.Chemical penetration enhancers: a patent review.Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation.Niosomes in sustained and targeted drug delivery: some recent advances.The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review.Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation.Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers.Nanocarrier for the transdermal delivery of an antiparkinsonian drugNanoemulsion components screening and selection: a technical note.Formulation, antimicrobial and toxicity evaluation of bioceramic based ofloxacin loaded biodegradable microspheres for periodontal infection.Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic stuAddressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors.A logical approach to optimize the nanostructured lipid carrier system of irinotecan: efficient hybrid design methodology.Microscopic and spectroscopic evaluation of novel PLGA-chitosan Nanoplexes as an ocular delivery system.An HPTLC method for the determination of minocycline in human plasma, saliva, and gingival fluid after single step liquid extraction.Inverse targeting of diclofenac sodium to reticuloendothelial system-rich organs by sphere-in-oil-in-water (s/o/w) multiple emulsion containing poloxamer 403.Transdermal therapeutic system of enalapril maleate using piperidine as penetration enhancer.Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation.Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: utility in Caco-2 intestinal absorption studies.Optimisation of polyherbal gels for vaginal drug delivery by Box-Behnken statistical design.Development and performance evaluation of alginate-capped amphotericin B lipid nanoconstructs against visceral leishmaniasisDevelopment and bioavailability assessment of ramipril nanoemulsion formulationApplication of a validated stability-indicating densitometric thin-layer chromatographic method to stress degradation studies on moxifloxacinValidated high-performance thin-layer chromatography method for determination of trigonelline in herbal extract and pharmaceutical dosage formFeasibility of proniosomes-based transdermal delivery of frusemide: formulation optimization and pharmacotechnical evaluationOil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigationInhalation of alendronate nanoparticles as dry powder inhaler for the treatment of osteoporosisAssessment of ocular pharmacokinetics and safety of Ganciclovir loaded nanoformulationsDevelopment and evaluation of nanosized niosomal dispersion for oral delivery of GanciclovirMelanoma treatment: from conventional to nanotechnologyDevelopment and validation of stability indicating reversed-phase liquid chromatographic method for simultaneous quantification of methotrexate and teriflunomide in nanoparticles and marketed formulation
P50
Q34817042-4B784950-6DDB-4B7F-A2F4-93B5BB0EDFA9Q34882750-02EBC587-3DA7-4F26-B7CE-68A7C3AF319BQ36548827-4D795941-2D60-427E-855C-C668915F78AAQ37347837-2AE135A2-B7B0-4A1F-AE08-B40F7C0CB96DQ37516306-13E540CC-2757-4E40-80E2-6601FF5EC2B5Q37529814-216B122B-3AE1-44C6-BF3B-ACEEE2302236Q37569156-B0939164-846B-45E5-BE50-7EBB51F143FBQ37618808-54500AEE-4151-4130-A3AE-45BCFA7E5165Q37854074-F1927D47-4AB4-472F-AADE-D51E1BB035C8Q39116581-0E384FF0-40F7-4D7B-B4A3-D40BD9960582Q39260613-547C30BF-058C-4CE0-BA1E-2E8E987FE375Q41826280-88CE86E8-0900-4920-9594-4A256107FCE9Q41989363-4EB554F4-8EB6-4C90-AB58-203020B929AAQ42833049-836A3B37-24A2-4609-B3D3-186558057450Q43761050-953D877B-5859-4A9A-ABC5-4348C181C30FQ44630776-BBD56828-6CEA-41DC-91D1-8D3A7846E71EQ44717370-9B9933C1-81DB-48B2-8103-32F17BDE9662Q45433967-821E8AB3-8369-472E-B86C-3559CEA0BBCDQ46165871-C1F14949-3452-4979-8B51-CDABCCB995C9Q46612377-28F8416E-70FC-480F-B086-44FEAB741799Q46660555-8323A10D-E9DD-4BA2-A240-5E014BE24D08Q46913848-213B7D17-1F70-41BA-9C7D-126BF9256963Q46951320-8A6294A1-7263-4429-9965-4F5EE2F993EDQ51075524-35D61627-56D0-4A23-9AF3-5A77483B42AEQ59003768-B1F55552-46FE-4DC9-9D2D-CCD66B37FD7BQ79382704-0664E6E8-46C9-4BBE-A265-DC55468CA933Q80041875-D1A02775-B367-45E3-8E0C-A7C974836CD8Q80852783-85A0C552-0544-4E12-A8E6-C2880EAC5C3FQ80990690-1E17F7A4-C8C6-48F7-8234-FDC4F354883FQ82366864-8179777B-006E-4D8B-94C2-D8880B6FA0AFQ83367856-EBAEF15A-E281-4866-99BE-28CF259E05C5Q83839591-36AD3EE9-A3CB-4A08-A317-E3FB20AA8743Q84499500-579DEF63-D507-4815-8364-629B80739099Q90863671-B6AB8FEC-0938-4382-A750-4EFFF870358AQ91079790-7481CE02-92DF-45B2-86AB-29E688854FB3
P50
description
researcher ORCID ID = 0000-0001-5301-5298
@en
wetenschapper
@nl
name
Sushama Talegaonkar
@ast
Sushama Talegaonkar
@en
Sushama Talegaonkar
@es
Sushama Talegaonkar
@nl
type
label
Sushama Talegaonkar
@ast
Sushama Talegaonkar
@en
Sushama Talegaonkar
@es
Sushama Talegaonkar
@nl
prefLabel
Sushama Talegaonkar
@ast
Sushama Talegaonkar
@en
Sushama Talegaonkar
@es
Sushama Talegaonkar
@nl
P108
P1153
12243707100
P31
P496
0000-0001-5301-5298